Final CMS Aducanumab Decision Limits Coverage to Clinical Tr

In a final decision on the funding of the controversial Alzheimer's drug aducanumab, federal officials largely stuck to their draft plan to limit Medicare payment to patients enrolled in clinical trials.

Related Keywords

United States , American , Howard Fillit , Centers For Medicare , National Coverage Determination , Alzheimer Drug Discovery Foundation , Medicaid Services , Medscape Medical News , Drug Discovery Foundation , Chiquita Brooks Lasure , Alzheimers Disease , Lzheimer Disease , Aducanumab , Dementia , Health Insurance , Drug Costs , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Medicare , Amyloid Beta , Amyloid Plaque , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Financing , Data Collect ,